An early look at FDA trends

By Maureen Martino and Tracy Staton

It's never too early to identify trends, and what better place to look than the FDA? The environment at the world's premier regulatory agency can have a significant impact the U.S. as well as the world markets, so it's always wise to keep an eye on happenings at the FDA.

In that vein, here's an early look at four FDA trends we've identified so far this year. We'll see how these play out by the end of the year.

Read more on

Suggested Articles

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.

Analysts are cautiously optimistic Amgen's $13.4 billion purchase of Celgene's psoriasis blockbuster Otezla will pay off.